Clinical Social Workers in West Haven, UT Accepting Medicare
7 Clinical Social Workers found. Showing 1 - 7
 Jessica Morgan Jensen, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4645 Midland Dr Ste 2, West Haven, UT 84401 Phone: 801-332-9139 |
 Nathan Brown, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 4645 Midland Dr Ste 2, West Haven, UT 84401 Phone: 801-814-1618 |
Mrs. Amy J Hopkins, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3856 S 3600 W, West Haven, UT 84401 Phone: 801-690-6520 |
Michael Alan Vanderdoes, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4630 S 3500 W Ste 1, West Haven, UT 84401 Phone: 385-626-9227 |
Jenifer Layne Gorder, MSW, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2129 Whiston St, West Haven, UT 84401 Phone: 801-548-2231 |
Jennie Houtz, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2130 W 1800 S, West Haven, UT 84401 Phone: 385-417-4182 |
Karen Dodd, L.C.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2459 S Laurel St, West Haven, UT 84401 Phone: 801-941-8242 |
News Archive
NAI receives U.S. patent allowance for sustained release beta-alanine products
Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance of its patent application directed to sustained release formulations of beta-alanine.
Dental flossing and other consumer behaviors contribute to elevated levels of PFAS in the body
A new study suggests certain types of consumer behaviors, including flossing with Oral-B Glide dental floss, contribute to elevated levels in the body of toxic PFAS chemicals. PFAS are water- and grease-proof substances that have been linked with numerous health problems.
Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
MRI helps early diagnosis of schizophrenia
Researchers may have discovered a new way that may ultimately assist in the early diagnosis of schizophrenia - by utilizing MRI to study the patient's brain.
› Verified 6 days ago
Clinical Social Workers
Counselors
Occupational Therapists
Dentists